AI주식인사이트AI Stock Insight
C

동화약품

000020KOSPI

50.0 / 100

Reference Date: 2026-10-23

Financial Score19.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Slightly up 3.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Dongwha Pharm operates in pharmaceuticals, medical device manufacturing and sales, and other financial services. In 2023, sales increased by 6.78% to 496,394 million won compared to the previous year, but operating profit fell by 98.09%. Key subsidiaries include Medissei (medical device manufacturer), TS Care (Vietnam-based pharmaceutical distribution chain), and Dongwha Kripton (venture investment firm).

Number of Employees

838people

Average Salary

71.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
38.45Industry Average 15.000.0Point

2.6x industry avg (risky)

PBR
0.37Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE
0.96Industry Average 8.001.0Point

Well below industry avg

Debt Ratio
9.44Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲17.8% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼63.3% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 2.9% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (34%)

Current 5,290Won52-week high 6,67052-week low 4,550
1-month return4.0Point

1m +3.52% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral[기재정정]반기보고서 (2026.06)2026-10-02